Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
11/20/2008
 
First Published:
5/23/2003
1.
Phase I/II Study of Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma (Phase I Closed to Accrual as of 3/29/06)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
NCI
NCI-03-C-0162
NCI-5855, 5855, NCT00062036
Last Modified:
1/1/2001
 
First Published:
7/1/2000
2.
Phase II Randomized Study of Interleukin-2 Gene Versus Methotrexate in Patients With Recurrent or Refractory Advanced Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 01/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI, Pharmaceutical / Industry
MCC-12051
MCC-IRB-5482, VALENTIS-IL2-2001, NCI-G00-1810, NCT00006033
Last Modified:
12/23/2008
3.
Phase I Study of Interleukin-2 Gene-Modified Autologous or Partially HLA-Matched Allogeneic Neuroblastoma Cells for Refractory or Recurrent Neuroblastoma (Summary Last Modified 06/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
under 21 at diagnosis
NCI
SJCRH-CYGENE
SJCRH-CYGNE2, NCI-H96-0005, NCT00002748
Last Modified:
12/24/2008
4.
Phase I Study of Interleukin-2 Gene-Modified Autologous Tumor Cell Vaccine in Advanced Breast Cancer (Summary Last Modified 11/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
DUMC-93122
NCI-H96-1111
5.
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
75 and under
Other
H6408
NCT00058799
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute